Table1 Effect of PTX and OHP on thermal hyperalgesia and cold hyperalgesia in CIPN models. The heat thermal thresholds and cold sensitivity (as measures of the development of sensory abnormalities) were measured by plantar test and cold plate test, respectively. Data are expressed as a mean ± SEM. *p < 0.05 as compared to VEHOHP **p < 0.01 as compared to VEHPTX, using a nonparametric Mann–Whitney test. VEHPTX / VEHOHP, vehicle of PTX or OHP; PTX, paclitaxel; OHP, oxaliplatin.
Plantar test (SEC—MEAN ± SEM) | Cold plate test (N SIGNS IN 300 SEC—MEAN ± SEM) | ||||
|---|---|---|---|---|---|
2 weeks of treatment | 3 weeks of treatment | ||||
baseline | 2 weeks mid-treatment | baseline | 3 weeks mid-treatment | ||
VEHPTX | 12.94 ± 0.58 | 12.78 ± 0.60 | VEHOHP | 14.81 ± 1.55 | 13 ± 1.25 |
PTX | 13.33 ± 0.44 | 13.60 ± 0.58 | OHP | 15.10 ± 1.58 | 13.76 ± 1.18 |
4 weeks of treatment | 6 weeks of treatment | ||||
baseline | 4 weeks end of treatment | baseline | 6 weeks end of treatment | ||
VEHPTX | 13.27 ± 0.41 | 14.25 ± 0.61 | VEHOHP | 20.90 ± 2.13 | 13.52 ± 1.11 |
PTX | 12.87 ± 0.46 | 11.95 ± 0.58 ** | OHP | 18.70 ± 2.66 | 25.26 ± 4.56 * |
